Interpace Biosciences (IDXG) investor relations material

Company overview and business model

• Provides esoteric molecular diagnostic testing and pathology services focused on cancer risk evaluation, with a primary emphasis on thyroid cancer diagnostics after discontinuing a pancreatic cancer test due to loss of reimbursement.

• Commercializes proprietary genomic tests, notably ThyGeNEXT® and ThyraMIR® v2, targeting indeterminate thyroid nodules to inform patient management and reduce unnecessary surgeries.

• Customers include physicians, hospitals, cancer centers, commercial labs, and clinics, with revenue from Medicare, Medicaid, commercial payers, and direct client billing.

• Developing new molecular diagnostic tests for pancreatic cyst and Barrett's Esophagus cancer risk, with timelines of 12-24 months for pancreatic and unlikely before 2030 for Barrett's.

Financial performance and metrics

• ThyGeNEXT® and ThyraMIR® v2 revenue grew at a 19.7% CAGR from 2022 to 2025, reaching $34.8 million in 2025 with a gross profit of $21.2 million and adjusted EBITDA of $4.4 million.

• As of June 30, 2026, cash and cash equivalents were $2.7 million, with pro forma stockholders' equity of $40.1 million after the offering.

• Immediate dilution to new investors is estimated at $2.01 per share, with an as-adjusted net tangible book value of $4.46 per share post-offering.

Use of proceeds and capital allocation

• Net proceeds of approximately $17.8 million (up to $20.6 million with full over-allotment) will be used for working capital, capital expenditures, general corporate purposes, and potentially for R&D and acquisitions.

• No current commitments for acquisitions or investments; proceeds may support development of new cancer diagnostic tests.